In-vivo Bioluminescence Imaging System

体内生物发光成像系统

• 批准号: 7220311
• 负责人: Linda A Toth
• 金额: $ 20.34万
• 依托单位: SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7220311
• 关键词: Animal Model; Animals; Area; Bioluminescence; Cell Survival; Cells; Communicable Diseases; Data Quality; Development; End Point; Equipment; Faculty; Financial Support; Funding; Gene Expression; Genes; Housing; Image; Individual; Infection; Inflammation; Laboratory Animal Medicine; Lead; Life; Light Cell; Link; Location; Luciferases; Malignant Neoplasms; Measures; Methods; Monitor; Mus; Neoplasm Metastasis; Pattern; Production; Public Health; Range; Reporter Genes; Research; Research Infrastructure; Research Personnel; Series; Stress; System; Technology; Testing; Therapeutic; Time; Tissues; Transgenic Animals; Tumor Cell Line; United States National Institutes of Health; Universities; Work; antimicrobial; cancer therapy; in vivo; luciferin; medical schools; oncology; pathogen; photonics; programs; promoter; response; tumor; tumor growth

DESCRIPTION (provided by applicant): We are applying for funds to purchase a Xenogen IVIS(r) Imaging System 100 Series bioluminescence imaging (BLI) workstation to provide our investigators with the ability to conduct in vivo BLI studies. In vivo BLI is a technological advancement that utilizes emitted light from cells or tissues to study real-time gene expression or activity in live animals. BLI requires inserting into cells a luciferase reporter gene under the control of a selected gene promoter. The luciferase-tagged cells are then injected into a mouse or other small animal, or expressed in a transgenic animal, so that their location and activity can be monitored noninvasively via photonic emissions subsequent to the systemic administration of the substrate D-luciferin. In vivo BLI has major applications in the areas of infectious diseases, oncology, and gene expression. The commercial availability and our in-house ability to produce a broad range of tumor cell lines that express luciferase linked to various promoters provides our cancer investigators with the ability to use BLI to study real-time tumor growth, metastasis and therapeutic responses in vivo. BLI also permits real-time assessment of the development and spread of infections, which will lead to a better understanding of host-pathogen interactions and the efficacy of antimicrobial treatments in the context of living animal models. BLI offers several advantages over more traditional assessment methods, including 1) high sensitivity in measuring semi-quantitative differences in cell viability or function within and between groups; 2) a more efficient and accurate assessment of the distribution of expression (that is, tumor expression or patterns of infection, inflammation and stress can be efficiently monitored throughout an entire animal, thus avoiding the possibility of missing unanticipated positive areas); and 3) the ability to assess the same individual subjects at serial time points, thus allowing the use of more sensitive and statistically more powerful repeated-measures paradigms, and removing the need for multiple terminal endpoints. SIU School of Medicine, and its core Research Imaging Facility and Division of Laboratory Animal Medicine will provide the infrastructure and financial support to keep the requested equipment in working order and promote optimal use by participating faculty and staff. The precise and definitive results afforded by in vivo BLI are not possible with the existing technology at our university. Thus, the requested Xenogen BLI system and accessories will greatly benefit our major users and enhance their federally funded research programs through the production of larger volumes of higher quality data. These benefits will also extend to faculty beyond the listed users, thereby increasing their competitiveness for NIH funding. Relevance to Public Health: The IVIS 100 system provides the means by which our investigators will be able to more rapidly and precisely characterize the course of cancer and infectious diseases. Also, the same equipment permits a more efficient way in which effective cancer treatments can be developed and tested.

描述（由申请人提供）：我们正在申请资金购买Xenogen IVIS（r）成像系统100系列生物发光成像（BLI）工作站，以使我们的研究人员能够进行体内BLI研究。体内BLI是一项技术进步，它利用细胞或组织发出的光来研究活体动物中的实时基因表达或活性。BLI需要在选定的基因启动子的控制下将荧光素酶报告基因插入细胞中。然后将标记有β-淀粉酶的细胞注射到小鼠或其他小动物中，或在转基因动物中表达，使得在全身施用底物D-β-淀粉酶后，可以通过光子发射非侵入性地监测它们的位置和活性。体内BLI在感染性疾病、肿瘤学和基因表达领域具有主要应用。商业可用性和我们生产广泛的表达与各种启动子连接的荧光素酶的肿瘤细胞系的内部能力为我们的癌症研究人员提供了使用BLI研究体内实时肿瘤生长，转移和治疗反应的能力。BLI还允许实时评估感染的发展和传播，这将有助于更好地了解宿主-病原体相互作用以及在活体动物模型中抗菌治疗的有效性。与传统的评估方法相比，BLI提供了几个优点，包括1）在测量组内和组间细胞活力或功能的半定量差异方面具有高灵敏度; 2）更有效和准确地评估表达的分布（也就是说，可以在整个动物中有效地监测肿瘤表达或感染、炎症和应激的模式，从而避免遗漏非预期阳性区域的可能性）;和3）在连续时间点评估相同个体受试者的能力，从而允许使用更敏感和统计学上更强大的重复测量范例，并消除对多个终末终点的需要。SIU医学院及其核心研究成像设施和实验动物医学部门将提供基础设施和财政支持，以保持所需设备的工作状态，并促进参与教师和工作人员的最佳使用。体内BLI提供的精确和明确的结果是不可能与我们大学的现有技术。因此，所要求的Xenogen BLI系统和配件将极大地有利于我们的主要用户，并通过产生更大量的更高质量的数据来增强他们的联邦资助的研究计划。这些好处也将延伸到教师以外的上市用户，从而提高他们的竞争力NIH的资金。与公共卫生的相关性：IVIS 100系统为我们的研究人员提供了更快速、更精确地描述癌症和传染病过程的手段。此外，同样的设备可以更有效地开发和测试有效的癌症治疗方法。